SCHEMBL507109

SCHEMBL507109

N#Cc1ccc(CBr)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.41
BRD4 O60885 1/20 0.36
CHEK1 O14757 3/20 0.36
EGLN2 Q96KS0 1/20 0.34
NAMPT P43490 1/20 0.34
GRM2 Q14416 2/20 0.33
PARP14 Q460N5 1/20 0.33
ALOX5AP P20292 1/20 0.33
FEN1 P39748 1/20 0.33
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRB1 P18505 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
GABRB2 P47870 1/20 0.33
GABRA4 P48169 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5871776 0.84 AR (0.39) ARBRD4CHEK1EGLN2NAMPT
SCHEMBL453185 0.79 CHEK1 (0.44) ARBRD4CHEK1EGLN2NAMPT
SCHEMBL452012 0.79 BRD4 (0.36) ARBRD4CHEK1EGLN2NAMPT
SCHEMBL128983 0.79 AR (0.38) ARBRD4CHEK1EGLN2NAMPT
SCHEMBL31044563 0.79 GRM5 (0.36) FFAR1FFAR4
SCHEMBL24146512 0.79 GAA (0.38) ARBRD4CHEK1EGLN2NAMPT
SCHEMBL2643631 0.79 BRD4 (0.36) ARBRD4CHEK1EGLN2NAMPT
SCHEMBL453184 0.79 BRD4 (0.39) ARBRD4CHEK1EGLN2NAMPT
SCHEMBL452013 0.79 BRD4 (0.36) ARBRD4CHEK1EGLN2NAMPT
SCHEMBL2760434 0.79 CYP2A6 (0.48) ARBRD4CHEK1EGLN2NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388542-A1 ANALOGUES OF PENTAMIDINE AND USES THEREFOR AURANSA INC. (US) 2025-12-25 US disclosed
US-12497382-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2025-12-16 US disclosed
US-12473314-B2 Phospholipid compounds and uses thereof GILEAD SCIENCES, INC. (US) 2025-11-18 US disclosed
US-12428420-B2 Tricyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2025-09-30 US disclosed
EP-4619098-A1 GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS Eli Lilly and Company (US) 2025-09-24 EP disclosed
CN-119874674-A GLP-1R modulating compounds 吉利德科学公司 2025-04-25 CN disclosed
EP-4537828-A2 PHOSPHOLIPID COMPOUNDS AND USES THEREOF Gilead Sciences, Inc. (US) 2025-04-16 EP disclosed
EP-4200301-B1 PHOSPHOLIPID COMPOUNDS AND USES THEREOF GILEAD SCIENCES INC (US) 2025-02-26 EP disclosed
US-20250034132-A1 PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF INSILICO MEDICINE IP LIMITED (HK) 2025-01-30 US disclosed
US-20250034182-A1 PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. 2025-01-30 US disclosed
US-6774110-B2 ANTITHROMBOTIC ACTIVITY AND HIGH ORAL BIOAVAILABILITY; E.G. N-AMINOSULFONYL-D-DIPHENYLALANYL-L-PROLYL-((4-AMIDINOPHENYL)METHYL)AMIDE LG LIFE SCIENCES LTD. (KR) 2004-08-10 US disclosed
US-20040102448-A1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade PHARMACIA CORPORATION 2004-05-27 US disclosed
US-20040006230-A1 Useful as inhibitors of serine proteases; for therapy and prophylaxis of thrombotic conditions including coronary artery and cerebrovascular diseases PHARMACIA CORPORATION 2004-01-08 US disclosed
US-6664255-B1 1-alkylamido-3-amino substituted; inhibiting serine proteases PHARMACIA CORPORATION 2003-12-16 US disclosed
EP-1292579-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE Pharmacia Corporation (US) 2003-03-19 EP disclosed
US-20020169113-A1 Orally available peptidic thrombin inhibitors LG LIFE SCIENCES LTD. (KR) 2002-11-14 US disclosed
EP-1202975-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE Pharmacia Corporation (US) 2002-05-08 EP disclosed
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors ABBOTT LABORATORIES 2002-02-14 US disclosed
WO-2001087854-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE PHARMACIA CORPORATION (US) 2001-11-22 WO disclosed
WO-2000069834-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE PHARMACIA CORPORATION (US) 2000-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388542-A1 ANALOGUES OF PENTAMIDINE AND USES THEREFOR MALT1, SLC38A7, SLC7A1 AR 546/4885BRD4 3287/4885CHEK1 2857/4885
US-20250034132-A1 PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF EGLN3, EGLN2, EGLN1 AR 4581/4885BRD4 161/4885CHEK1 4537/4885
US-20040102448-A1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade TFPI, PLAT, TFPI2 AR 3525/4885BRD4 1217/4885CHEK1 1861/4885
US-12428420-B2 Tricyclic heterocycles as FGFR inhibitors FGFR3, FGFR1, FGFR2 AR 1333/4885BRD4 281/4885CHEK1 132/4885
US-20020169113-A1 Orally available peptidic thrombin inhibitors F2, SERPINC1, TFPI AR 4703/4885BRD4 1766/4885CHEK1 4075/4885
US-20250034182-A1 PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME PHOSPHO1, SGMS1, SGMS2 AR 4605/4885BRD4 1445/4885CHEK1 2833/4885
US-20040006230-A1 Useful as inhibitors of serine proteases; for therapy and prophylaxis of thrombotic conditions including coronary artery and cerebrovascular diseases PRSS1, SERPINC1, SERPINE1 AR 4489/4885BRD4 1454/4885CHEK1 936/4885
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors FNTA, FNTB, SLC10A1 AR 4525/4885BRD4 3180/4885CHEK1 3835/4885
US-12473314-B2 Phospholipid compounds and uses thereof PHOSPHO1, SGMS2, SGMS1 AR 4609/4885BRD4 810/4885CHEK1 2415/4885
US-12497382-B2 GLP-1R modulating compounds GLP1R, GIPR, GPR119 AR 1757/4885BRD4 1246/4885CHEK1 3844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.